---
title: "BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299083430.md"
description: "LifeSci Capital reiterated a Buy rating on BlossomHill Therapeutics with a $32 price target, citing strong Phase 1/2 data for BH-30643 in C797S-mutant patients. Guggenheim also initiated coverage with a Buy rating and a $30 target."
datetime: "2026-09-15T17:35:56.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299083430.md)
  - [en](https://longbridge.com/en/news/299083430.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299083430.md)
generator: "portal-rs"
---

# BlossomHill: Buy Rating Reiterated as BH-30643 Data Strengthen Case for C797S-Focused Path; $32 Price Target Maintained

In a report released today, Charles Zhu from LifeSci Capital maintained a Buy rating on BlossomHill Therapeutics, Inc., with a price target of $32.00.

Charles Zhu has given his Buy rating due to a combination of factors, most notably the emerging clinical profile of BH-30643 from the SOLARA Phase 1/2 study in C797S-mutant patients. The updated WCLC 2026 data show a maintained overall response rate in the mid-40% range, alongside encouraging treatment durability with most patients remaining on therapy at roughly seven months of median follow-up, which supports confidence in the drug’s efficacy trajectory.

Safety findings, including liver-related laboratory abnormalities, appear consistent with expectations and manageable, with no Hy’s Law cases observed, reinforcing the therapeutic window for BH-30643. Together with a clear path toward a C797S-focused accelerated approval discussion in late 2026 and a discounted cash flow valuation that supports an unchanged $32 price target, Zhu views BlossomHill’s risk-reward profile favorably and sees meaningful upside potential in the shares.

In another report released on September 1, Guggenheim also initiated coverage with a Buy rating on the stock with a $30.00 price target.

### Related Stocks

- [BLSM.US](https://longbridge.com/en/quote/BLSM.US.md)

## Related News & Research

- [BlossomHill Plans Pivotal Phase 2 Trial of BH-30643 in Lung Cancer for Q1 2027](https://longbridge.com/en/news/304849584.md)
- [BlossomHill Therapeutics to Present BH-30236 Clinical Data at ASH Meeting](https://longbridge.com/en/news/304271556.md)
- [BlossomHill Therapeutics Presents at Guggenheim’s 3rd Annual Healthcare Innovations Conference](https://longbridge.com/en/news/304110623.md)
- [OXY: Strong Q3 cash generation advanced debt reduction and the >$4B annual cash flow goal by 2030](https://longbridge.com/en/news/305061493.md)
- [14 companies sold 108,247 Bitcoin in 2026, but here’s why it’s not what it looks like!](https://longbridge.com/en/news/305139945.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**